SCHEMBL2132004

SCHEMBL2132004

O=C(O)N1CCC(NC2CN(C(=O)c3ccc(-c4ccccc4)cc3)C2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 3/20 0.53
HPGD P15428 2/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
EPHX1 P07099 1/20 0.51
POLB P06746 3/20 0.51
MGLL Q99685 2/20 0.50
FASN P49327 2/20 0.50
HTR1A P08908 1/20 0.50
HTR1B P28222 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
HSD11B1 P28845 1/20 0.50
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129559 0.93 EPHX1 (0.56) SMN1; SMN2ALDH1A1LMNAHPGDMAPK1
SCHEMBL2130059 0.89 HSD11B1 (0.62) SMN1; SMN2ALDH1A1LMNAHPGDMAPK1
SCHEMBL2610263 0.84 USP30 (0.60) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL2134021 0.84 ABL1 (0.53) SMN1; SMN2ALDH1A1HPGDMAPK1MEN1
SCHEMBL2130909 0.84 MGLL (0.60) SMN1; SMN2ALDH1A1EPHX1MGLLPTPN2
SCHEMBL2731835 0.83 MCHR1 (0.54) MEN1KMT2AEPHX1HSD11B1
SCHEMBL2131274 0.83 MCHR1 (0.54) MEN1KMT2AEPHX1HSD11B1
SCHEMBL2131338 0.83 MGLL (0.50) SMN1; SMN2ALDH1A1LMNAHPGDMAPK1
SCHEMBL8158991 0.82 LMNA (0.67) SMN1; SMN2ALDH1A1LMNAHPGDMAPK1
SCHEMBL2133223 0.82 MGLL (0.47) SMN1; SMN2ALDH1A1LMNAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US disclosed
EP-2630139-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-08-28 EP disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US disclosed
WO-2012054721-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICAL NV (BE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL SMN1; SMN2 1754/4885ALDH1A1 552/4885LMNA 1887/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL SMN1; SMN2 1754/4885ALDH1A1 552/4885LMNA 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.